Abstract
[Objective] β-Sitosterol-modified ginsenoside Rb1 liposomes （β-Rb1-Lip） were prepared to reduce the degradation of Rb1 and enhance the lipid-lowering effects of ginsenoside Rb1. [Methods] β-sitosterol-modified ginsenoside Rb1 liposomes were prepared by the thin-film hydration method. The biosafety of the liposomes was assessed using the MTT assay. The inhibition of lipid droplet accumulation in 3T3-L1 adipocytes by β-Rb1-Lip was investigated using Oil Red O staining and triglyceride （TG） content measurement with an enzyme-linked immunosorbent assay. [Results] The prepared β-Rb1-Lip liposomes had an encapsulation efficiency of 83.74% and an average particle size of 198 nm. The release rate of Rb1 from β-Rb1-Lip was about 80% within 12 hours, demonstrating a good sustained-release effect. Regarding lipid-lowering activity, β-Rb1-Lip at 50 μmol/L showed a significant inhibitory rate of intracellular lipid droplets. Compared to the same concentration of Rb1 monomer, β-Rb1-Lip had a more significant inhibitory effect on the accumulation of lipid droplets in 3T3-L1 cells and did not exhibit cytotoxicity. [Conclusion] β-Rb1-Lip has high encapsulation efficiency, small particle size, and obvious sustained-release characteristics. It can continuously release the active component ginsenoside Rb1, enhance its lipid-lowering efficacy, and reduce the dosage, providing support for the development of Rb1 lipid-lowering products.
Publication Date
9-11-2024
First Page
1
Last Page
6,80
DOI
10.13652/j.spjx.1003.5788.2023.81195
Recommended Citation
Xiaoyan, YOU; Hui, LIU; Xu, DUAN; and Yue, CHEN
(2024)
"Investigating the inhibitory effect of β-Rb1-Lip on lipid droplet accumulation in 3T3-L1 adipocytes,"
Food and Machinery: Vol. 40:
Iss.
7, Article 1.
DOI: 10.13652/j.spjx.1003.5788.2023.81195
Available at:
https://www.ifoodmm.cn/journal/vol40/iss7/1
References
[1] NORDESTGAARD B G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology[J]. Circulation Research, 2016, 118（4）: 547-563.
[2] KARR S. Epidemiology and management of hyperlipidemia[J]. Am J Manag Care, 2017, 23: S139-S148.
[3] KHAN S S, PETITO L C, HUANG X. Body mass index, adverse pregnancy outcomes, and cardiovascular disease risk[J]. Circ Res, 2023, 133: 725-735.
[4] JACOBSON T A, ITO M K, MAKI K C. National lipid association recommendations for patient-centered management of dyslipidemia part 1: full report[J]. Clin Lipidol, 2015, 9（2）: 129-169.
[5] LIU Y, ZHU H Y, ZHOU W, et al. Anti-inflammatory and anti-gouty-arthritic effect of free ginsenoside Rb1 and nano ginsenoside Rb1 against MSU induced gouty arthritis in experimental animals[J]. Chem Biol Interact, 2020, 332: 109285.
[6] ZHOU R R, HE D, ZHANG H C, et al. Ginsenoside Rb1 protects against diabetes-associated metabolic disorders in Kkay mice by reshaping gut microbiota and fecal metabolic profiles[J]. Ethnopharmacol, 2023, 303: 115997.
[7] 马艺鑫, 宁顺宇, 陈丝, 等. 基于N-糖基化修饰组学探究人参皂苷Rb1改善高脂血症大鼠脂代谢紊乱机制[J]. 中国中西医结合杂志, 2023, 43（9）: 1 100-1 107.
MA Y X, NING S Y, CHEN S, et al. Exploring the mechanism of ginsenoside Rb1 to improve lipid metabolism disorder in hyperlipidaemic rats based on N-glycosylation modification histology[J]. Chinese Journal of Integrative Medicine, 2023, 43（9）: 1 100-1 107.
[8] ZHOU P, XIE W J, HE S B, et al. Ginsenoside Rb1 as an anti-diabetic agent and its underlying mechanism analysis[J]. Cells, 2019, 8（3）: 204-222.
[9] ZOU H, ZHANG M, ZHU X T, et al. Ginsenoside Rb1 improves metabolic disorder in high-fat diet-induced obese mice associated with modulation of gut microbiota[J]. Frontiers in Microbiology, 2022, 13: 826487.
[10] DU L X, LU H L, XIAO Y F, et al. Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles[J]. Sci Rep, 2023, 13（1）: 18472.
[11] 卢婧霞, 郑祖国, 徐志猛, 等. 植物甾醇降血脂机制研究进展[J]. 中国中药杂志, 2019, 44（21）: 4 552-4 559.
LU J X, ZHENG Z G, XU Z M, et al. Progress in the study of lipid-lowering mechanism of phytosterols[J]. China Journal of Chinese Materia Medica, 2019, 44（21）: 4 552-4 559.
[12] NIYONZIMA N, HALVORSEN B, SPORSHEIM B. Complement activation by cholesterol crystals triggers a subsequent cytokine response[J]. Mol Immunol, 2017, 84: 43-50.
[13] WANG G F, GUAN L H, ZHOU D. Serum high-density lipoprotein cholesterol is significantly associated with the presence and severity of pulmonary arterial hypertension: a retrospective cross-sectional study[J]. Adv Ther, 2020, 37（5）: 2 199-2 209.
[14] LIU W L, LIU J H, LIU W, et al. Improved physical and in vitro digestion stability of a polyelectrolyte delivery system based on layer-by-layer self-assembly alginate-chitosan-coated nanoliposomes[J]. Agric Food Chem, 2013, 61（17）: 4 133-4 144.
[15] CUI T T, JIA A R, YAO M K, et al. Characterization and caco-2 cell transport assay of chito-oligosaccharides nano-liposomes based on layer-by-layer coated[J]. Molecules, 2021, 26（14）: 4 144-4 159.
[16] RAFIEE Z, BARZEGAR M, SAHARI M A. Nanoliposomal carriers for improvement the bioavailability of high-valued phenolic compounds of pistachio green hull extract[J]. Food Chemistry, 2017, 220: 115-122.
[17] 杨艳芳, 谢向阳, 杨阳, 等. 粒径与表面电荷影响脂质体体内药物靶向递送的研究进展[J]. 药学学报, 2013, 48（11）: 1 644-1 650.
YANG Y F, XIE X Y, YANG Y, et al. Advances in the study of particle size and surface charge affecting in vivo targeted drug delivery by liposomes[J]. Acta Pharmaceutica Sinica, 2013, 48（11）: 1 644-1 650.
[18] ZHANG J, HAN X Z, LI X, et al. Core-shell hybrid liposomal vesicles loaded with panax notoginsenoside: preparation, characterization and protective effects on global cerebral ischemia/reperfusion injury and acute myocardial ischemia in rats[J]. Int J Nanomedicine, 2012, 7: 4 299-4 310.
[19] 周柳莎, 胡香莲, 俞瑜媛, 等. 荞麦糖肽脂质体的制备及其稳定性和缓释研究[J]. 中国粮油学报, 2024, 39（4）: 119-130.
ZHOU L S, HU X L, YU Y Y, et al. Preparation, stability and sustained release of buckweat glycopetide liposomes[J]. Journal of the Chinese Cereals and Oils Association, 2024, 39（4）: 119-130.
[20] HOANG T, RAMADASS K, LOC T T. Novel drug delivery system based on ginsenoside Rb1 loaded to chitosan/alginate nanocomposite films[J]. Nanosci Nanotechnol, 2019, 19（6）: 3 293-3 300.